Malignant Mesothelioma: Clinical and Imaging Findings

Chapter

Abstract

Malignant mesothelioma is a rare tumor. The incidence has been rising since the 1970s with a male to female ratio of 5:1 which is likely due to the increased frequency of occupational exposure to asbestos in men. The clinical and imaging features of malignant mesothelioma vary widely depending on the stage of presentation. A significantly high index of suspicion is required to make a diagnosis due to the nonspecific nature of the symptoms, signs, and early radiology. Invasive surgical procedures are often required to obtain adequate tumor tissue samples to secure the diagnosis.

Keywords

Malignant mesothelioma Mesothelioma surgical treatment Mesothelioma imaging Mesothelioma symptoms Mesothelioma clinical findings 

References

  1. 1.
    Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Verschraegen C. Mesothelioma: incidence and survival rates in the United States. Proc Am Soc Clin Oncol. 2003;22:869.Google Scholar
  3. 3.
    Bégin R. Asbestos related diseases. In: Harber P, Schenker MB, Balmes JR, editors. Occupational and environmental respiratory disease. St. Louis: Mosby-Year Book; 1996. p. 293–321.Google Scholar
  4. 4.
    Sheard JDH, et al. Pneumothorax and malignant mesothelioma in patients over the age of 40. Thorax. 1991;46:584.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Law MR, Hodson ME, Heard BE. Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour. Thorax. 1982;37:810.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Ruffie P, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1981;7:1157.Google Scholar
  7. 7.
    Olesen LL, Thorshauge H. Thrombocytosis in patients with malignant pleural mesothelioma. Cancer. 1988;62:1194.PubMedCrossRefGoogle Scholar
  8. 8.
    Rudd RM. Malignant mesothelioma. Br Med Bull. 2010;93:105–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg. 2009;1(1):38–48.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Antman KH. Current concepts: malignant mesothelioma. N Engl J Med. 1980;303:200–2.PubMedCrossRefGoogle Scholar
  11. 11.
    Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med. 2006;27:193–213.PubMedCrossRefGoogle Scholar
  12. 12.
    Gotfried MH, Quan SF, Sobonya RE. Diffuse epithelial pleural mesothelioma presenting as a solitary lung mass. Chest. 1983;84:99.PubMedCrossRefGoogle Scholar
  13. 13.
    Ng CS, Munden RF, Libshitz HI. Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases. Clin Radiol. 1999;54:415–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Mujoomdar AA, Sugarbaker DJ. Diffuse pleural malignancies. In: Sugarbaker DJ, Bueno R, Krasna MJ, Mentzer SJ, Zellos L, editors. Adult chest surgery. New York: McGraw Hill Medical; 2009. p. 838–48.Google Scholar
  15. 15.
    Heelan RT, Rusch VW, Begg CB, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039–47.PubMedCrossRefGoogle Scholar
  16. 16.
    Bernard F, Sterman D, Smith RJ, et al. Metabolic Imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;9:713–72.CrossRefGoogle Scholar
  17. 17.
    Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126:11–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2006;132:763–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Ismail-Khan R, Robinson LA, Williams CC, et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13:255–63.PubMedGoogle Scholar
  20. 20.
    Metintas M, Ozdemir N, Isiksoy S, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. J Comput Assist Tomogr. 1995;19:370–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Agarwal PP, Seely JM, Matzinger FR, et al. Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy. Radiology. 2006;241:589–94.PubMedCrossRefGoogle Scholar
  22. 22.
    Rai AJ, Flores RM, Mathew A, et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med. 2010;48(2):271–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–6.PubMedCrossRefGoogle Scholar
  24. 24.
    West SD, Lee GYC. Management of malignant pleural mesothelioma. Clin Chest Med. 2006;27:335–54.PubMedCrossRefGoogle Scholar
  25. 25.
    Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax. 1976;31:15–24.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Edge SB, Byrd DR, Compton CC, editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Division of Cardiothoracic SurgerySt. Vincent’s Hospital, MelbourneMelbourneAustralia
  2. 2.Department of Thoracic SurgeryMount Sinai Medical CenterNew YorkUSA

Personalised recommendations